BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has high selectivity over ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Direct multi-KRAS inhibitors, QTX3034 and QTX3544, exhibit potent activity against established and novel resistance mechanisms to ...

ISM6166 was nominated as a PCC as an oral, broad-spectrum pan‑KRAS ON/OFF inhibitor, designed to overcome resistance ...

Executives from BridgeBio Oncology Therapeutics (NASDAQ:BBOT) outlined the company’s strategy to build what they call the “Best in RAS” pipeline during an Oppenheimer-hosted discussion, emphasizing in ...

HYDRACs are a class of proteomimetic polymers designed to mark harmful proteins, like MYC and KRAS, for destruction rather than merely block their activity.

KRAS is the most frequently mutated oncogene across all human cancers. Although different KRAS mutations have long been thought to exert the same cancer-driving effects, a new study led by UT ...

KRASG12C-targeted therapies like sotorasib and adagrasib have been approved, but resistance challenges persist, necessitating further research into RAS(ON) therapies. Revolution Medicines is ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window And in this ...